Kelli Eglinger
Payments from drug & device makers
Across 149 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$580
- AbbVie$420
- Amgen$163
- Boehringer Ingelheim$153
- E.r. Squibb & Sons, L.L.C.$151
- Exact Sciences$125
- plus $665 from 17 others
What the payments were for
- Food & beverage$2,258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $580 |
| AbbVie | 36 | $420 |
| Amgen | 11 | $163 |
| Boehringer Ingelheim | 8 | $153 |
| E.r. Squibb & Sons, L.L.C. | 20 | $151 |
| Exact Sciences | 6 | $125 |
| Novo Nordisk | 6 | $99 |
| Amarin Pharma, Inc. | 6 | $87 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $77 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Pfizer | 4 | $59 |
| Lilly USA, LLC | 3 | $49 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Biogen | 1 | $25 |
| GSK | 1 | $23 |
| Novartis | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| Bayer | 1 | $15 |
| Abbott | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Grifols USA, LLC | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$2,258 in reported general payments places this provider in the 70th percentile of 233 medical providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $69,206 |
| OzempicSemaglutide | 41 | $64,923 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $49,285 |
| XareltoRivaroxaban | 33 | $39,882 |
| JanuviaSitagliptin Phosphate | 33 | $39,364 |
| EliquisApixaban | 28 | $35,279 |
| MounjaroTirzepatide | 20 | $34,579 |
| Repatha SureclickEvolocumab | 16 | $17,495 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,702 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $2,951 |
| Atorvastatin Calcium | 243 | $1,891 |
| Levothyroxine Sodium | 198 | $1,796 |
| Rosuvastatin Calcium | 150 | $1,469 |
| Amlodipine Besylate | 152 | $1,294 |
| Omeprazole | 78 | $1,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $153 | $69,20661 claims |
| Novo NordiskOzempic | $99 | $64,92341 claims |
| GSKTrelegy Ellipta | $23 | $49,28532 claims |
| PfizerEliquis | $59 | $35,27928 claims |
| Lilly USA, LLCMounjaro | $49 | $34,57920 claims |
| AbbVieSynthroid | $420 | $70314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 233 medical providers in West Virginia.
Other medical in Baker
- Katherine BoggsSouth Charleston$46K
- Lowell LarewMorgantown$31K
- Katie CarpenterSouth Charleston$26K
- Lauren DillonBeckley$18K
- Angela HagerFarmington$16K
- Brandon CaragCharleston$16K
- Scott EthridgeCharleston$16K
- Kellie HanselSouth Charleston$12K
- Matthew MaynardElkins$10K
- Mohammad YousafCharleston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.